Login to Your Account



Market 'hearts' Kyprolis phase III interim results; big PFS outcome in MM

By Randy Osborne
Staff Writer

Monday, August 4, 2014

Investor jitters about cardiac side effects were quelled and full approval chances bolstered by interim phase III data from Amgen Inc.'s trial testing the second-generation proteasome inhibitor Kyprolis when combined with Revlimid and low-dose dexamethasone against relapsed multiple myeloma.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription